Landmark Trial: Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42%

A news report on October 26 describes a landmark trial in which a cancer vaccine reduced the risk of melanoma recurrence or death by 42%. This appears to be further coverage of the result first logged on Oct 22. The feed summary did not name the vaccine, trial phase or sponsor, so those details remain unverified.